Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scynexis has signed an exclusive licensing deal with Dechra Pharmaceuticals for the development and commercialization of SCY-641 to treat canine keratoconjunctivitis sicca (KCS).
Subscribe to our email newsletter
A cyclosporine derivative, SCY-641, is the first partnered compound from the Scynexis cyclophilin inhibitor platform, which includes a clinical candidate for the treatment of Hepatitis C, SCY-635.
Scynexis discovery research executive director Michael Peel said Dechra, with a strong presence in animal health and a history of successful new product introductions, is the ideal partner for SCY-641.
"We believe that this novel compound has the potential to offer a major advance in the treatment of dry eye in both animal and human health," Peel added.
Pursuant to the agreement, Dechra which gains worldwide animal health rights is responsible for the remaining clinical development and commercialisation of SCY-641.
Scynexis, which holds back human health rights to the compound, has earned an upfront fee and is entitled to obtain further payments based on development milestones, as well as double digit royalties on product sales.
The pre-clinical studies demonstrated that SCY-641 has immunosuppressive activity and can reduce ocular inflammation, promoting tear production.
Dechra chief executive Ian Page said, "The ophthalmic market is a key therapeutic sector for Dechra; the application of SCY-641 in the animal health market offers significantly improved clinical treatment of dry eye in animals and an excellent commercial opportunity."